Related Experiment Videos
[Fluvastatin in patients after heart transplantation]
1I. interní kardio-angiologická klinika Nemocnice U sv. Anny, Brno.
Insights
Fluvastatin effectively lowers high cholesterol and LDL-cholesterol in heart transplant patients. This statin is safe for use with immunosuppressive drugs like cyclosporine, showing no adverse effects.
Area of Science:
- Cardiology
- Pharmacology
- Transplantation Medicine
Background:
- Hyperlipoproteinaemia is a common complication following organ transplantation.
- Managing hyperlipoproteinaemia in transplant recipients is challenging due to potential drug interactions, particularly with immunosuppressants like cyclosporine.
Purpose of the Study:
- To evaluate the efficacy and safety of fluvastatin in heart transplant patients with hyperlipoproteinaemia.
- To assess the impact of fluvastatin on lipid profiles and its interaction with standard immunosuppressive therapy, including cyclosporine levels.
Main Methods:
- A study involving 15 heart transplant recipients with hyperlipoproteinaemia on triple immunosuppression.
- Administration of fluvastatin (20 mg daily) with monitoring of lipid levels (cholesterol, LDL, HDL, triglycerides), renal function (urea, creatinine), liver function tests, and cyclosporine levels at baseline and at 6 weeks, 3 months, and 6 months.
Main Results:
- Significant reductions in mean cholesterol levels from 7.66 mmol/l to 5.83 mmol/l (p < 0.001) and LDL-cholesterol from 4.82 mmol/l to 3.31 mmol/l (p < 0.001) were observed.
- No significant changes were noted in HDL-cholesterol, triglycerides, urea, creatinine, liver function tests, or cyclosporine levels.
- No clinical evidence of muscular damage was reported during the study period.
Conclusions:
- Fluvastatin is an effective treatment for hyperlipoproteinaemia in heart transplant patients.
- Fluvastatin demonstrates a favorable safety profile when used concurrently with standard immunosuppressive therapy, including cyclosporine, without compromising its levels or causing adverse effects.
Abstract:
Hyperlipoproteinaemia is one of the frequent posttransplantation problems. Administration of statins is complicated in patients after transplantation by concurrent imunosuppressive treatment, in particular by possible undesirable interaction with cyclosporin. In the presented study 15 patients after transplantation of the heart with hyperlipoproteinaemia were examined who were on a standard triple combination of immunosuppressive drugs. Fluvastatin was administered, 20 mg in the evening, and in intervals of 6 weeks, 3 months and 6 months after the onset of treatment the levels of cholesterol, LDL and HDL-cholesterol, triglycerides, urea, creatinine, liver terts and cyclosporine were followed up. The mean cholesterol level declined from 7.66 mmol/l during the 6rd week (p < 0.002), to 6.01 mmol/l during 3rd month and to 5.83 mol/l after the 6rd month (p < 0.001), LDL-cholesterol declined from 4.82 mmol/l and then 3.46 mmol/l and 3.31 mmol/l (p < 0.001). In the other investigated parameters no change recorded, incl. the cyclosporin levels. No clinical signs of muscular damage were recorded Fluvastatin thus does not only reduce effectively the cholesterol and LDL-cholesterol level but is also safe combination with immunosuppressive treatment.